NDAORALTABLETPriority Review
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Peganone (ethotoin) is an oral aromatic antiepileptic drug approved in 1957 for seizure management. It belongs to the hydantoin class of anticonvulsants and works by stabilizing neuronal membranes to reduce seizure activity. This legacy agent has been largely replaced by newer anticonvulsants with improved tolerability profiles.
LOE Approaching
Minimal team investment expected; legacy product with declining utilization and no active growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Peganone offers limited career momentum due to minimal hiring, stable but declining market demand, and lack of innovation initiatives. Roles on this product are typically support/maintenance functions rather than growth-focused positions, with limited visibility for career advancement.
Medical Science LiaisonCustomer Service Specialist
Worked on PEGANONE at Recordati? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.